Related Experiment Video
Updated: May 3, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma
Xiaoming Yao1, Ji-Fan Hu, Mark Daniels
1Medical Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA.
Abstract:
IGF-II is a mitogenic peptide that has been implicated in hepatocellular oncogenesis. Since the silencing of gene expression is frequently associated with cytosine methylation at cytosine-guanine (CpG) dinucleotides, we designed a methylated oligonucleotide (MON1) complementary to a region encompassing IGF2 promoter P4 in an attempt to induce DNA methylation at that locus and diminish IGF2 mRNA levels. MON1 specifically inhibited IGF2 mRNA accumulation in vitro, whereas an oligonucleotide (ON1) with the same sequence but with nonmethylated cytosines had no effect on IGF2 mRNA abundance. MON1 treatment led to the specific induction of de novo DNA methylation in the region of IGF2 promoter hP4. Cells from a human hepatocellular carcinoma (HCC) cell line, Hep 3B, were implanted into the livers of nude mice, resulting in the growth of large tumors. Animals treated with MON1 had markedly prolonged survival as compared with those animals treated with saline or a truncated methylated oligonucleotide that did not alter IGF2 mRNA levels in vitro. This study demonstrates that a methylated sense oligonucleotide can be used to induce epigenetic changes in the IGF2 gene and that inhibition of IGF2 mRNA accumulation may lead to enhanced survival in a model of HCC.
Insights
A novel methylated oligonucleotide (MON1) targeting the IGF2 gene successfully induced DNA methylation, reducing IGF2 mRNA levels. This epigenetic modification significantly improved survival in a hepatocellular carcinoma (HCC) mouse model.
Area of Science:
- Epigenetics
- Molecular Biology
- Oncology
Background:
- Insulin-like growth factor II (IGF-II) is a key mitogen in hepatocellular oncogenesis.
- Gene silencing is often linked to cytosine methylation at CpG dinucleotides.
Purpose of the Study:
- To investigate if a methylated oligonucleotide can induce DNA methylation at the IGF2 promoter P4 locus.
- To determine if this epigenetic modification can reduce IGF2 mRNA levels and impact hepatocellular carcinoma (HCC) progression.
Main Methods:
- Design and synthesis of a methylated oligonucleotide (MON1) targeting IGF2 promoter P4.
- In vitro assessment of MON1's effect on IGF2 mRNA accumulation.
- Induction of de novo DNA methylation in the IGF2 promoter region.
- In vivo evaluation of MON1 efficacy in an HCC mouse model (Hep 3B cells).
Main Results:
- MON1 specifically inhibited IGF2 mRNA accumulation in vitro.
- MON1 treatment induced de novo DNA methylation at the IGF2 promoter hP4.
- Mice treated with MON1 exhibited markedly prolonged survival compared to controls.
Conclusions:
- Methylated sense oligonucleotides can induce specific epigenetic changes in the IGF2 gene.
- Inhibition of IGF2 mRNA accumulation via MON1 demonstrates therapeutic potential for HCC.
Related Concept Videos
Epigenetic Regulation
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Experimental RNAi
Abnormal Proliferation
MicroRNAs
Epigenetic Regulation
X-chromosome...

